Capital Impact Advisors, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Capital Impact Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $88,232 - $129,502	-7,490 Reduced 11.17%	59,577 $1 Million
Q3 2023 Nov 14, 2023	BUY	$11.69 - $15.02 $245,150 - $314,984	20,971 Added 45.49%	67,067 $784,000
Q1 2023 May 23, 2023	BUY	$14.34 - $21.05 $21,466 - $31,511	1,497 Added 3.36%	46,096 $764,000
Q4 2022 Feb 14, 2023	SELL	$12.25 - $19.5 $180,099 - $286,689	-14,702 Reduced 24.79%	44,599 $829,000
Q3 2022 Nov 21, 2022	SELL	$7.06 - $15.52 $379,658 - $834,603	-53,776 Reduced 47.56%	59,301 $907,000
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $85,693 - $117,880	13,755 Added 13.85%	113,077 $793,000
Q1 2022 May 16, 2022	BUY	$5.31 - $8.31 $527,399 - $825,365	99,322 New	99,322 $823,000
Q4 2020 Feb 12, 2021	SELL	$2.97 - $3.83 $603,305 - $777,999	-203,133 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $60,721 - $121,210	23,265 Added 12.93%	203,133 $782,000
Q3 2019 Nov 14, 2019	BUY	$3.89 - $7.43 $699,686 - $1.34 Million	179,868 New	179,868 $948,000

332

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.35B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.